Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
CAMCEVI is a sterile formulation of leuprolide mesylate for subcutaneous injection. CAMCEVI is designed to deliver approximately 42 mg of leuprolide over 6 months.
Leuprolide mesylate is a synthetic nonapeptide analog of naturally occurring GnRH and is a GnRH agonist. The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-Lprolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide mesylate (salt) with the following structural formula. The pH of 50 mg/mL solution of leuprolide mesylate in water is approximately 5.7.
 |
CAMCEVI is supplied as a kit with a pre-filled, single-dose, sterile syringe for subcutaneous injection. Each pre-filled syringe delivers 42 mg leuprolide (equivalent to approximately 48 mg leuprolide mesylate), poly(D, L-lactide) (184 mg) polymer and N-methyl-2-pyrrolidone (136 mg).
CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.
CAMCEVI must be administered by a healthcare provider.
The recommended dose of CAMCEVI is 42 mg administered subcutaneously once every 6 months.
 |
 |
 |
Injectable emulsion: 42 mg leuprolide (equivalent to approximately 48 mg leuprolide mesylate) as a sterile, off-white to pale yellow, viscous, and opalescent emulsion in a single-dose, pre-filled syringe for subcutaneous injection.
CAMCEVI is a sterile, off-white to pale yellow, viscous and opalescent injectable emulsion supplied in a kit as a single-dose, pre-filled syringe. CAMCEVI is available as follows:
| Kit Contents | NDC |
| Injectable emulsion in a pre-filled syringe containing 42 mg leuprolide for subcutaneous injection, a sterile 18 gauge needle, a Point-Lok ®needle protection device, and Instructions for Use. |
69448-014-63 |
Store CAMCEVI at 2°C–8°C (36°F–46°F). Protect CAMCEVI from light by storing in the original package until time of use. Do not freeze or shake.
The rubber used in syringe tip cap and plunger stopper is not made of natural rubber latex.
Manufactured for: Accord BioPharma, Inc., 8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617 USA. By: Fareva Pau, Fareva Pau 1, Avenue du Bearn, IDRON, 64320, France. Revised: Nov 2023
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In an open-label, non-comparative clinical trial (FP01C-13-001), patients with advanced prostate cancer received CAMCEVI administered subcutaneously at a dose of 42 mg on Day 0 and Day 168. Of 137 patients enrolled, 93% received both doses of CAMCEVI.
Serious adverse reactions occurred in 15% of patients who received CAMCEVI, including 1% of patients who experienced subdural hematoma. Fatal adverse reactions occurred in 2% of patients, including cerebrovascular accident (0.7%) and pulmonary embolism (0.7%).
The most common adverse reactions (≥10%) occurring during a median follow-up duration of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity. Table 1 summarizes the adverse reactions in FP01C-13-001.
Table 1: Adverse Reactions Occurring in ≥5% of Patients - FP01C-13-001
| Adverse Reaction | N = 137 | |
| All Grades(%) | Grade 3-4(%) | |
| Vascular disorders | ||
| Hot flush a | 50 | 0 |
| Hypertension b | 15 | 0 |
| General disorders and administration site conditions | ||
| Injection site reactions c | 11 | 0 |
| Fatigue d | 10 | 0 |
| Infections and infestations | ||
| Upper respiratory tract infection e | 11 | 0 |
| Musculoskeletal and connective tissue disorders | ||
| Musculoskeletal pain f | 11 | 0 |
| Pain in extremity | 10 | 0 |
| Arthralgia | 7 | 0 |
| Renal and urinary disorders | ||
| Micturition urgency g | 6 | 0 |
| Nocturia | 6 | 0 |
| Nervous system disorders | ||
| Dizziness h | 5 | 0.7 |
| aincludes hot flush and flushing bincludes hypertension, essential hypertension, and blood pressure increased cincludes injection site pain, injection site erythema, injection site hemorrhage, injection site nodule, injection site paraesthesia, injection site pruritus, and injection site warmth dincludes fatigue and asthenia eincludes upper respiratory tract infection, sinusitis, and nasopharyngitis fincludes musculoskeletal pain, back pain, and bone pain gincludes micturition urgency and dysuria hincludes dizziness, dizziness postural, vertigo, and vertigo positional. |
||
The following adverse reactions have been identified during post approval use of leuprolide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
During postmarketing surveillance, which includes other dosage forms and other patient populations, the following adverse reactions were reported.
Allergic Conditions:anaphylactoid or asthmatic process, rash, urticaria, and photosensitivity reactions
Cardiovascular System:hypotension, myocardial infarction, pulmonary embolism
Central/Peripheral Nervous System:convulsion, peripheral neuropathy, spinal fracture/paralysis
Endocrine System:pituitary apoplexy, diabetes
Hepato-biliary disorder:drug-induced liver injury
Hematologic:white blood cells
Psychiatric:mood swings, including depression, suicidal ideation and attempt
Respiratory, thoracic and mediastinal disorder:interstitial lung disease
Musculoskeletal System:decreased bone density, tenosynovitis-like symptoms, fibromyalgia
Skin and Subcutaneous:injection site reactions
Urogenital System:prostate pain
No Information provided
Included as part of the PRECAUTIONS section.
CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment, declining thereafter to baseline levels or below by the end of the second week of treatment. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may develop during the first few weeks of CAMCEVI treatment. Patients treated with CAMCEVI may experience a temporary increase in bone pain, which can be managed symptomatically.
As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications.
Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Hyperglycemia may represent the development of diabetes mellitus or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes.
Increased risk of developing myocardial infarction, sudden cardiac death, and stroke has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.
Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.
Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI [see ADVERSE REACTIONS]. Manage patients receiving a GnRH agonist who experience convulsions according to current clinical practice.
Monitor serum levels of testosterone following injection of CAMCEVI. In the majority of patients treated with CAMCEVI, testosterone levels increased above baseline during the first week, and then declined thereafter to castration levels (<50 ng/dL) within 4 weeks [see Clinical Studies and ADVERSE REACTIONS].
Based on findings in animal studies and mechanism of action, CAMCEVI can cause fetal harm when administered to a pregnant woman. In animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus [see Use In Specific Population, CLINICAL PHARMACOLOGY].
Two year carcinogenicity studies were conducted with leuprolide in rats and mice. In rats, a dose-related increase of benign pituitary hyperplasia and benign pituitary adenomas was noted at 24 months when the drug was administered subcutaneously at high daily doses (0.6 to 4 mg/kg). There was a significant but not dose related increase of pancreatic islet cell adenomas in females and of testicular interstitial cell adenomas in males (highest incidence in the low dose group). In mice, no pituitary abnormalities were observed at a dose as high as 60 mg/kg for 2 years. Patients have been treated with leuprolide for up to 3 years with doses as high as 10 mg/day and for 2 years with doses as high as 20 mg/day without demonstrable pituitary abnormalities.
Mutagenicity studies have been performed with leuprolide using bacterial and mammalian systems. These studies provided no evidence of mutagenic potential.
Leuprolide may reduce male and female fertility. Administration of leuprolide to male and female rats at doses of 0.024, 0.24, and 2.4 mg/kg as monthly depot formulation for up to 3 months (approximately as low as 1/30 of the human dose based on body surface area using an estimated daily dose in animals and humans) caused atrophy of the reproductive organs, and suppression of reproductive function. These changes were reversible upon cessation of treatment.
Based on findings in animal studies and mechanism of action, CAMCEVI can cause fetal harm when administered to a pregnant woman [see CLINICAL PHARMACOLOGY]. There are no available data in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose (see data). Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.
Animal Data
Major fetal malformations were observed in developmental and reproductive toxicology studies in rabbits after a single administration of a monthly formulation of leuprolide administered on day 6 of pregnancy at test dosages of 0.00024, 0.0024, and 0.024 mg/kg (approximately 1/1500 to 1/15 the human dose based on body surface area using an estimated daily dose in animals and humans). Since a depot formulation was utilized in the study, a sustained exposure to leuprolide was expected throughout the period of organogenesis and to the end of gestation. Similar studies in rats did not demonstrate an increase in fetal malformations, however, there was increased fetal mortality and decreased fetal weights with the two higher doses of the monthly formulation of leuprolide in rabbits and with the highest dose in rats.
The safety and efficacy of CAMCEVI have not been established in females. There is no information regarding the presence of leuprolide in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in a breastfed child, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Males
Based on findings in animals and mechanism of action, CAMCEVI may impair fertility in males of reproductive potential [see WARNINGS AND PRECAUTIONS, Nonclinical Toxicology].
The safety and efficacy of CAMCEVI in pediatric patients have not been established.
Of the 137 patients who received CAMCEVI in the FP01C-13-001 study, 74% were 65 years of age or older, while 37% were 75 years of age or older. No overall differences in safety or effectiveness were observed between these patients and younger patients.
No Information provided
CAMCEVI is contraindicated in patients known to be hypersensitive to GnRH, GnRH agonist analogs, or any of the excipients in CAMCEVI. Anaphylactic reactions to GnRH agonist analogs have been reported in the medical literature.
Leuprolide, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy.
In humans, subcutaneous administration of single daily doses of leuprolide result in an initial increase in circulating levels of LH and FSH, leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males). However, continuous daily administration of leuprolide results in decreased levels of LH and FSH. In males, testosterone is reduced to below castration levels. These decreases generally occur within 2 to 4 weeks after initiation of treatment, and castration levels of testosterone in prostatic cancer patients have been demonstrated for periods of up to 5 years.
Mean serum testosterone concentrations transiently increased, then fell to below castrate threshold levels (≤ 50 ng/dL) within 3 weeks following administration of the dose of leuprolide, and generally remained below castrate thresholds levels throughout treatment.
Leuprolide concentration is variable, exhibiting an initial rapid increase followed by a rapid decline over the first 3 days before reaching steady concentrations for the duration of the dosing interval. The mean serum leuprolide Cmax was 94.5 and 99 ng/mL following the first and second doses of CAMCEVI, respectively. The mean serum concentration was maintained at 0.497–2.57 and 0.507–2.39 ng/ml after Day 3 post the first and second doses, respectively. The mean AUC0-6 was 224 and 268 day.ng/mL following the first and second doses of CAMCEVI, respectively.
The median Tmax of leuprolide was 3.2 and 2.1 hours following the first and second doses of CAMCEVI, respectively
The mean steady state volume of distribution of leuprolide was 27 L following an intravenous bolus in healthy male volunteers. Protein binding of leuprolide ranged from 43% to 49% in vitro.
The mean systemic clearance was 7.6 L/h and terminal elimination half life of approximately 3 hours following an intravenous bolus of leuprolide in healthy male volunteers.
Metabolism
Administration of radiolabeled leuprolide was metabolized to smaller inactive peptides which may then be further catabolized.
Excretion
Excretion of leuprolide has not been evaluated with CAMCEVI.
No clinically significant differences in the systemic exposure of leuprolide were observed based on age (51 to 88 years), race/ethnicity (White, Black, Asian), or body weight (54 to 134 kg). The effect of renal or hepatic impairment on the pharmacokinetics of leuprolide has not been evaluated.
The efficacy of CAMCEVI was evaluated in an open label, single arm, multinational study FP01C-13-001 (NCT02234115) in patients with advanced prostate carcinoma who have a baseline morning serum testosterone level >150 ng/dL and Eastern Cooperative Oncology Group performance status ≤ 2. CAMCEVI was administered subcutaneously at a dose of 42 mg initially on Day 0 and on Week 24.
The population (n = 137) had a median age of 71 years (range 51 to 88) and was 90% White, 6% Black, and 4% Asian. Disease stage was distributed as follows: 23% metastatic (M1), 27% locally advanced (T3/4 NX M0 or any T N1 M0), 26% localized (T1 or T2 N0 M0), and 24% not classifiable. The median testosterone concentration at baseline was 440 ng/dL.
The major efficacy outcome measure was medical castration rate, defined as achieving and maintaining serum testosterone suppression to ≤ 50 ng/dL by Week 4 through Week 48 of treatment. Following the first injection of CAMCEVI, serum testosterone levels were suppressed to ≤ 50 ng/dL by Week 4 (+/-7 days) in 98.5% of the patients; and from Week 4 through Week 48 in 97.0% of patients (95% CI: 92.2-98.9) estimated using the Kaplan-Meier method. The time course of percent change from baseline in testosterone suppression are shown in Figure 1. The percentage of patients with testosterone suppression to ≤ 20 ng/dL was 69.3% on Day 28.
Figure 1 :CAMCEVI Mean (95% CI) Percentage Change from Baseline in Serum Testosterone Concentration Over Time (N =137)
 |
In the clinical trial, PSA levels were monitored and were lowered on average by 51% after 4 weeks after administration of CAMCEVI, 83% after 3 months and remained suppressed throughout the 48 weeks of treatment. These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline correlates with clinical benefit.
Instructions for Use
You must read these complete instructions before you administer CAMCEVI for the first time.
CAMCEVI must be administered by a healthcare provider.
Instructions for Use
What is CAMCEVI?
CAMCEVI is a subcutaneous injection that provides long-acting gonadotropin releasing hormone (GnRH) agonist to patients. CAMCEVI contains a biodegradable polymer formulation dissolved in a biocompatible solvent that provides sustained release of leuprolide. CAMCEVI is supplied as a kit containing one sterile, pre-filled syringe for subcutaneous injection, one sterile 18-gauge needle, one Point-Lok® needle protection device, and Instructions for Use.
Dosage
The recommended dosing is 1 subcutaneous injection (42 mg leuprolide) every 6 months.
Before you begin to prepare CAMCEVI Injection
Read these critical instructions.
Do not substitute any of the components from the kit for administration.
CAMCEVI is packaged in a blister in the kit. Check to make sure the kit contains:
 |
®Point-Lok is a registered trademark of Smiths Medical
Bring CAMCEVI to room temperature
To bring CAMCEVI to room temperature:
STEP 1: Remove CAMCEVI kit from refrigerator. Open carton and remove blister.
Allow pre-filled syringe to sit at room temperature for 30 minutes prior to subcutaneous injection.
Prepare the syringe
Follow these steps to prepare CAMCEVI for use:
STEP 1 : Examine all contents of the package. Do not use if any component is damaged.
STEP 2 : Check the expiration date on the syringe. Do not use if the expiration date has passed.
STEP 3 :The use of gloves is recommended during syringe assembly and administration.
STEP 4 :On a clean, dry surface, remove pre-filled syringe (A) and needle cartridge (B) from the blister carton. Visually inspect the contents prior to use.
 |
STEP 5 : Â Remove the gray cap from the syringe (A). Twist the clear cap off the bottom of the needle cartridge (B).
STEP 6 : Â Attach the needle (B) to the end of the syringe (A) by pushing and turning the needle until firmly connected to the syringe. Do not over twist the needle and strip the threading.
 |
Assembled Pre-Filled Syringe
 |
Select an injection site
To select an injection site, use these guidelines:
STEP 1 : Choose an injection site on the upper- or mid-abdominal area with sufficient soft or loose subcutaneous tissue that has not recently been used. Clean the injection site with an alcohol swab.
 |
Do NOT inject in areas with brawny or fibrous subcutaneous tissue or locations that can be rubbed or compressed (i.e., with a belt or clothing waistband). In addition, avoid applying heat directly to the site of Camcevi injection.
Inject CAMCEVI
Follow these steps to inject CAMCEVI:
STEP 1 : Pull the blue cover off the needle (B). Use standard sharps safety techniques to avoid needle sticks.
STEP 2 :Use standard aseptic technique when performing the injection. Grab and bunch the skin around the injection site with one hand. Insert the needle at a 90° angle to the skin surface, and then release the bunched skin.
 |
STEP 3 : Inject the full contents of the syringe with a slow and steady push on the plunger, and then withdraw the needle at the same 90° angle used for insertion.
STEP 4 : Do not remove the needle from the syringe. Use the enclosed
Point-Lok® device to prevent needle sticks.
Retrieve the Point-Lok® needle protection device from the Camcevi kit and place it on a secured, flat surface with its largest surface base touching the surface as shown in the diagram below.
Immediately after use of the needle, gently insert the exposed needle into the Point-Lok® device opening at the top of the Point- Lok® device. (see Figure 1 below)
Push the needle into the top opening until it is fully inserted into the Point-Lok® device. This action will seal the needle tip and lock the needle firmly into the Point-Lok® device. (see Figure 2 below)
 |
After use, place the used syringe with needle protected in a suitable sharps container. Dispose of contaminated product in a safe manner according to Centers for Disease Control and Prevention, USA and Federal/State/Local regulations (EPA, OSHA) and health care facility guidelines or local equivalent.
